Multicell Techs Stock Performance
The company secures a Beta (Market Risk) of 0.0, which conveys not very significant fluctuations relative to the market. the returns on MARKET and Multicell Techs are completely uncorrelated.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Multicell Techs has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable technical and fundamental indicators, Multicell Techs is not utilizing all of its potentials. The current stock price uproar, may contribute to short-horizon losses for the private investors. ...more
Multicell |
Multicell Techs Relative Risk vs. Return Landscape
If you would invest 0.00 in Multicell Techs on September 13, 2024 and sell it today you would earn a total of 0.00 from holding Multicell Techs or generate 0.0% return on investment over 90 days. Multicell Techs is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of pink sheets are less volatile than Multicell, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Multicell Techs Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Multicell Techs' investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Multicell Techs, and traders can use it to determine the average amount a Multicell Techs' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| MCET |
Based on monthly moving average Multicell Techs is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Multicell Techs by adding Multicell Techs to a well-diversified portfolio.
Multicell Techs Fundamentals Growth
Multicell Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Multicell Techs, and Multicell Techs fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Multicell Pink Sheet performance.
| Return On Asset | -1.36 | |||
| Profit Margin | (0.31) % | |||
| Operating Margin | (0.60) % | |||
| Current Valuation | 1.22 M | |||
| Shares Outstanding | 5 B | |||
| Price To Sales | 0.01 X | |||
| Revenue | 49.32 K | |||
| Cash And Equivalents | 281.12 K | |||
| Total Debt | 36.43 K | |||
| Cash Flow From Operations | (1.09 M) | |||
| Total Asset | 126.22 K | |||
| Retained Earnings | (50.74 M) | |||
| Current Asset | 295 K | |||
| Current Liabilities | 1.54 M | |||
About Multicell Techs Performance
Assessing Multicell Techs' fundamental ratios provides investors with valuable insights into Multicell Techs' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Multicell Techs is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
MultiCell Technologies, Inc., a biopharmaceutical company, develops novel therapeutics and discovery tools for the treatment of neurological disorders, hepatic disease, cancer, and interventional cardiology and peripheral vessel applications. MultiCell Technologies, Inc. was founded in 1962 and is headquartered in Woonsocket, Rhode Island. Multicell Techs operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 2 people.Things to note about Multicell Techs performance evaluation
Checking the ongoing alerts about Multicell Techs for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Multicell Techs help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Multicell Techs generated a negative expected return over the last 90 days | |
| Multicell Techs has some characteristics of a very speculative penny stock | |
| Multicell Techs currently holds 36.43 K in liabilities. Multicell Techs has a current ratio of 0.19, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Multicell Techs until it has trouble settling it off, either with new capital or with free cash flow. So, Multicell Techs' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Multicell Techs sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Multicell to invest in growth at high rates of return. When we think about Multicell Techs' use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 49.32 K. Net Loss for the year was (380.07 K) with profit before overhead, payroll, taxes, and interest of 49.32 K. | |
| Multicell Techs currently holds about 281.12 K in cash with (1.09 M) of positive cash flow from operations. |
- Analyzing Multicell Techs' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Multicell Techs' stock is overvalued or undervalued compared to its peers.
- Examining Multicell Techs' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Multicell Techs' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Multicell Techs' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Multicell Techs' pink sheet. These opinions can provide insight into Multicell Techs' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Multicell Pink Sheet Analysis
When running Multicell Techs' price analysis, check to measure Multicell Techs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Multicell Techs is operating at the current time. Most of Multicell Techs' value examination focuses on studying past and present price action to predict the probability of Multicell Techs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Multicell Techs' price. Additionally, you may evaluate how the addition of Multicell Techs to your portfolios can decrease your overall portfolio volatility.